Arcutis Biotherapeutics Community
NasdaqGS:ARQT Community- 1 Narratives written by author
- 0 Comments on narratives written by author
- 30 Fair Values set on narratives written by author
Community Investing Ideas
AN
Consensus Narrative from 7 Analysts
FDA PDUFA Date And Payer Expansion Will Unlock Opportunity
Key Takeaways Expanding ZORYVE's indications and payer coverage is expected to significantly boost revenue and market potential. Partnerships and strategic market shifts are poised to drive sales growth and improve financial health towards break-even.
View narrativeUS$21.00
FV
30.2% undervalued intrinsic discount44.31%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
16users have followed this narrative
1 day ago author updated this narrative